Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

VEGF inhibitors make blood

Nature Medicine volume 12, pages 732–734 (2006)Cite this article

Findings in mice suggest that treatment with VEGF inhibitors prompts the upregulation of erythropoietin (Epo), a powerful cytokine and regulator of blood cell development. Could Epo be dulling the therapeutic effects of VEGF inhibition?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: VEGF inhibitor treatment causes feedback upregulation of Epo, VEGF and PlGF.

Kim Caesar

References

  1. Carmeliet, P. Nature 438, 932–936 (2005).

    Article  CAS  Google Scholar 

  2. Tam, B.Y.Y. et al. Nat. Med. 12, 793–800 (2006).

    Article  CAS  Google Scholar 

  3. Willett, C.G. et al. J. Clin. Oncol. 23, 8136–8139 (2005).

    Article  Google Scholar 

  4. Casanovas, O., Hicklin, D.J., Bergers, G. & Hanahan, D. Cancer Cell 8, 299–309 (2005).

    Article  CAS  Google Scholar 

  5. Heeschen, C. et al. Blood 102, 1340–1346 (2003).

    Article  CAS  Google Scholar 

  6. Kertesz, N., Wu, J., Chen, T.H., Sucov, H.M. & Wu, H. Dev. Biol. 276, 101–110 (2004).

    Article  CAS  Google Scholar 

  7. Kamba, T. et al. Am. J. Physiol. Heart Circ. Physiol. 290, H560–H576 (2006).

    Article  CAS  Google Scholar 

  8. LeCouter, J. et al. Science 299, 890–893 (2003).

    Article  CAS  Google Scholar 

  9. Cleaver, O. & Melton, D.A. Nat. Med. 9, 661–668 (2003).

    Article  CAS  Google Scholar 

  10. Hardee, M.E., Arcasoy, M.O., Blackwell, K.L., Kirkpatrick, J.P. & Dewhirst, M.W. Clin. Cancer Res. 12, 332–339 (2006).

    Article  CAS  Google Scholar 

  11. Batra, S., Perelman, N., Luck, L.R., Shimada, H. & Malik, P. Lab Invest. 83, 1477–1487 (2003).

    Article  CAS  Google Scholar 

  12. Yasuda, Y. et al. Br. J. Cancer 84, 836–843 (2001).

    Article  CAS  Google Scholar 

  13. Leyland-Jones, B. et al. J. Clin. Oncol. 23, 5960–5972 (2005).

    Article  CAS  Google Scholar 

  14. Stuben, G. et al. J. Cancer Res. Clin. Oncol. 127, 346–350 (2001).

    Article  CAS  Google Scholar 

  15. Bohlius, J. et al. J. Natl. Cancer Inst. 98, 708–714 (2006).

    Article  CAS  Google Scholar 

  16. Ribatti, D., Vacca, A., Roccaro, A.M., Crivellato, E. & Presta, M. Eur. J. Clin. Invest. 33, 891–896 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Transgene Technology and Gene Therapy, KU Leuven, Flanders Interuniversity Institute for Biotechnology (VIB), Leuven, Belgium

    Christian Fischer, Peter Carmeliet & Edward M Conway

Authors
  1. Christian Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Carmeliet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward M Conway
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fischer, C., Carmeliet, P. & Conway, E. VEGF inhibitors make blood. Nat Med 12, 732–734 (2006). https://doi.org/10.1038/nm0706-732

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0706-732

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing